IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#4233
Positioning
Market Dominance
Finance, Insurance, And Real Estate
Trading
$83M
Claudius Tsang
We are a blank check company incorporated in the British Virgin Islands as a business company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses, which we refer to throughout this prospectus as our initial business combination. Our executive offices are located at The Sun’s Group Center, 29th Floor, 200 Gloucester Road, Wan Chai Hong Kong.
Headcount
—
HQ Base
CENTRAL,
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
X-AXIS: EV/EBITDA (LOWER = CHEAPER) | Y-AXIS: ROE (HIGHER = ELITE) | RED CIRCLE = ASPC ANALYSIS TARGET
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$SII SPROTT INC. | 75 | 91 | 87 | 98 | - | - | 15.7% | 12.8% | 48.9% | 37.0% | 28.8% | 14.9% | 2.5% | 0.0x | $1.1B | VS | |
$PUK PRUDENTIAL PLC | 73 | 88 | 97 | 80 | - | - | 13.2% | 1.4% | 100.0% | 97.0% | 23.8% | 11.8% | 2.7% | 5.0x | $21.5B | VS | |
$NMR NOMURA HOLDINGS INC | 72 | 81 | 92 | 87 | - | - | 9.9% | 0.6% | 84.5% | 70.0% | 7.3% | 14.9% | 0.0% | 923.0x | $18.3B | VS | |
$PSLV Sprott Physical Silver Trust | 69 | 82 | 80 | 98 | - | - | 17.3% | 17.7% | 100.0% | 100.0% | 100.0% | 1643.8% | 0.0% | 0.0x | $5.0B | VS | |
$UFCS UNITED FIRE GROUP INC | 68 | 81 | 93 | 76 | 5.0x | 3.5x | 13.2% | 4.1% | 99.9% | 14.7% | 11.1% | 9.2% | 2.1% | 16.0x | $775M | VS | |
$SLF SUN LIFE FINANCIAL INC | 68 | 83 | 95 | 63 | - | - | 12.6% | 0.9% | 32.0% | 31.3% | 7.9% | -12.9% | 4.3% | 24.0x | $37.8B | VS | |
$CBOE Cboe Global Markets, Inc. | 68 | 75 | 63 | 77 | 21.3x | 15.7x | 24.0% | 13.7% | 41.7% | 32.4% | 26.4% | 8.2% | 1.1% | 30.0x | $25.7B | VS | |
$PHYS Sprott Physical Gold Trust | 67 | 64 | 82 | 91 | - | - | 22.5% | 22.8% | 101.8% | 100.0% | 100.0% | 138.9% | 0.0% | 0.0x | $8.4B | VS | |
$VTMX Vesta Real Estate Corporation, S.A.B. de C.V. | 67 | 69 | 77 | 80 | - | - | 8.8% | 5.8% | 98.7% | 75.7% | 88.5% | 17.6% | 4.3% | 34.0x | $2.2B | VS | |
$GLDM World Gold Trust | 66 | 54 | 85 | 92 | 11.3x | 11.3x | - | 27.1% | 100.0% | 98.9% | 459.9% | 333.4% | 0.0% | 0.0x | $43.7B | VS | |
$ASPC ASPAC III Acquisition Corp. | 34 | 24 | 23 | 49 | 23.3x | 43.4x | 126.6% | 1.9% | - | - | - | - | 0.0% | 54.0x | $83M | ||
| SECTOR BENCH | - | - | - | - | - | 11.9x | 7.8x | 8.9% | 1.2% | 76.5% | 17.0% | 21.5% | 10.8% | 1.9% | 0.5x | - | REF |
ASPAC III Acquisition Corp. (ASPC) receives a "Avoid" rating with a composite score of 33.7/100. It ranks #4233 out of 7,333 stocks in our coverage universe and carries a 1-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
Equity capital efficiency
Asset base utilization
Financial leverage load
Direct cash return
Claudius Tsang
Chief Executive Officer
24
19
25
Audit Verdict: Lower quality and stability scores may indicate governance concerns.
No recent insider transactions available for ASPC
In-line with peers — no strong momentum signal
Expensive relative to fundamentals — limited margin of safety
Weak fundamentals — higher risk of value trap
High volatility — wider range of outcomes increases timing risk
Aggressive spending — empire-building risk, dilutive growth
Below-average composite — caution warranted
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Finance, Insurance, And Real Estate sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
Projection based on user-defined inputs. Re-calculated daily against current market data.
Reverse DCF Framework — Mauboussin Methodology
Institutional-grade Reverse DCF analysis. This model identifies the growth hurdles embedded in current market prices. When implied growth is significantly lower than historical or projected rates, a margin of safety may exist. Re-audited daily.
No analyst ratings for ASPC.
View All RatingsInsufficient data for Financial Analysis
| Factor | Global | Sector | Tilt |
|---|---|---|---|
| PROFITABILITY | 24 | 9 | +15ALPHA |
| MOMENTUM | 49 | 51 | -2NEUTRAL |
| VALUATION | 23 | 6 | +17ALPHA |
| INVESTMENT | 19 | 2 | +17ALPHA |
| STABILITY | 25 | 17 | +8ALPHA |
| SHORT INT | 50 | 56 | -6DRAG |
Global = full universe. Sector = relative to industry peers. Positive tilt indicates idiosyncratic strength.
ROE proxy 126.6% (sector 8.9%)
GM N/A vs sector 77%, OM N/A vs sector 17%
Capital turnover N/A
Rev growth N/A, 2yr history
Interest coverage N/A
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
Our quantitative model flags ASPAC III Acquisition Corp. with an Avoid rating, assigning a composite score of 33.7/100 and 1 out of 5 stars. Ranked #4233 of 7,333 stocks, ASPC falls in the bottom tier across key factors. Historically, stocks with this profile have faced elevated risk of underperformance and capital loss.
ASPAC III Acquisition Corp. registers a weak quality score of just 24/100, indicating significant profitability challenges. The company reports a return on equity of 126.6% (sector avg: 8.9%). Low quality scores are often associated with businesses in turnaround mode, early-stage growth, or structurally challenged industries.
ASPC registers a value score of just 23/100, suggesting the stock trades at a significant premium to its fundamental metrics. Key valuation metrics include a P/E ratio of 23.29x, an EV/EBITDA of 43.35x, a P/B ratio of 29.49x. High-premium valuations like this require strong future execution to avoid multiple compression, and downside risk is elevated if growth disappoints.
ASPAC III Acquisition Corp.'s investment score of 19/100 suggests limited reinvestment activity. Key growth metrics include a return on assets of 1.9% (sector: 1.2%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
ASPC is currently showing below-average momentum at 49/100, which may indicate weakening institutional interest or negative sentiment shifts. Revenue growth data is not currently available, while a beta of 0.23 reflects its sensitivity to broader market moves. Investors should note that declining momentum can precede further price weakness, though contrarian opportunities sometimes emerge at these levels.
ASPC's stability score of 25/100 signals elevated volatility and/or leverage concerns. Key stability metrics include a beta of 0.23 and a debt-to-equity ratio of 54.00x (sector avg: 0.5x). Investors should be prepared for wider-than-average price swings and consider position sizing accordingly to manage portfolio risk.
The short interest score of 50/100 for ASPC suggests somewhat elevated bearish positioning by institutional traders. Specific risk factors include elevated leverage (D/E: 54.00x), micro-cap liquidity risk. With a $83M market cap (micro-cap), ASPAC III Acquisition Corp. may experience above-average volatility. Investors should consider whether the short thesis has merit or if it creates a potential short-squeeze opportunity.
ASPAC III Acquisition Corp. is a micro-cap company in the Finance, Insurance, And Real Estate sector, ranked #0 of 50 in its sector (100th percentile) and #4233 of 7,333 overall (42nd percentile). Key comparisons include ROE of 126.6% exceeding the 8.9% sector median. This top-quartile standing reflects exceptional competitive strength relative to Finance, Insurance, And Real Estate peers.
While ASPC currently exhibits a AVOID profile, superior opportunities exist within the FINANCE, INSURANCE, AND REAL ESTATE sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Finance, Insurance, And Real Estate Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Investment (19) would have the largest impact on the composite score.
EV/EBITDA 458% ABOVE SECTOR MEDIAN
ROE 1319% ABOVE SECTOR MEDIAN (FAVORABLE)
Debt/Equity 10920% ABOVE SECTOR MEDIAN
AUDIT DATA AS OF SEP 30, 2025 (Q2 FY2025)
We rate ASPAC III Acquisition Corp. (ASPC) as Avoid with a composite score of 33.7/100 at a current price of $12.03. The stock falls in the bottom quintile of our universe across key quantitative factors, and the multi-factor weakness suggests a high probability of continued underperformance.
The rating is primarily driven by strength in momentum (49th percentile) and stability (25th percentile), which together account for the majority of the composite score. Offsetting weakness in investment (19th percentile) and value (23th percentile) tempers our overall conviction. We assign a Narrow Moat rating (40/100), High uncertainty, and Standard capital allocation.
Key items to watch: valuation compression risk if growth disappoints. Any material change in these dynamics could warrant a reassessment of our rating. The moat trend is stable, which suggests the competitive landscape is stable for now.
ASPAC III Acquisition Corp. holds a top-quartile position (#0 of 50) within the Finance, Insurance, And Real Estate sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 33.7/100 places it at rank #4233 in our full 7,333-stock universe. At $83M in market capitalization, ASPAC III Acquisition Corp. is a small-cap player in the Finance, Insurance, And Real Estate space, which limits certain scale advantages but may allow for more agile strategic execution.
Momentum indicators (49th percentile) are neutral regarding the near-term price trend. Revenue growth data is unavailable, limiting our ability to confirm whether momentum is fundamentally supported.
Margin data is not available for ASPAC III Acquisition Corp., which limits our assessment of the company's cost structure and operating efficiency. We rely on factor-based signals to infer business quality in the absence of detailed margin data.
At a current price of $12.03, ASPAC III Acquisition Corp. is trading at a premium to fundamental value. Our value factor score of 23/100 reflects a composite assessment across multiple valuation metrics including price-to-earnings, price-to-book, EV/EBITDA, and price-to-sales ratios relative to both sector peers and the broader market. The premium valuation implies the market is pricing in significant future growth or quality improvements that are not yet fully reflected in current fundamentals.
The stock currently trades at a P/E of 23.3x (a 95% premium to the sector median of 11.9x), EV/EBITDA of 43.4x (at a premium), P/B of 29.5x. The above-sector P/E multiple suggests the market is pricing in superior growth or quality, which our analysis finds only partially justified by current fundamentals.
Returns on equity of 126.6% exceed the cost of equity for most companies, indicating genuine shareholder value creation and a reinvestment engine that compounds wealth over time.
The Avoid rating (composite 33.7/100) reflects multi-factor weakness, and historically, stocks in this scoring range have underperformed the market by a meaningful margin.
Below-average quality (24th percentile) raises durability concerns about the fundamental profile and increases the risk of negative earnings surprises.
We assign a High uncertainty rating to ASPAC III Acquisition Corp.. Key risk factors include below-average price stability (25th percentile), weak quality scores (24th percentile), low beta of 0.23 — while defensive, this may indicate limited upside participation in bull markets. The wide range of potential outcomes widens our fair value estimate and increases the possibility of permanent capital impairment. Investors considering this name should size positions accordingly and demand a meaningful margin of safety before initiating.
Specific risk factors that inform our assessment include: below-average price stability (25th percentile); weak quality scores (24th percentile); low beta of 0.23 — while defensive, this may indicate limited upside participation in bull markets. Each of these factors independently widens the distribution of potential outcomes, and in combination they create a risk profile that demands careful position sizing. The stability factor at the 25th percentile and quality factor at the 24th percentile provide a quantitative summary of the overall risk landscape.
We identify limited risk mitigants at this time, which contributes to our high uncertainty assessment. Investors should monitor for improvement in balance sheet metrics, margin stability, and business predictability that could warrant a downgrade in our risk assessment over time.
We rate ASPAC III Acquisition Corp.'s capital allocation as Standard. Management has shown adequate — though not exceptional — stewardship of shareholder capital. Returns on equity stand at 126.6%, and the balance sheet is managed within acceptable parameters (D/E: 54%). Exemplary allocators typically sustain ROE above 20% and D/E below 50%; ASPAC III Acquisition Corp. falls short on at least one dimension.
There is room for improvement in optimizing the capital structure or enhancing shareholder returns. Absent a dividend, the overall capital allocation framework would benefit from either higher reinvestment returns, improved balance sheet efficiency, or increased shareholder distributions. We will monitor for signs of strategic improvement that could warrant an upgrade.
In summary, ASPAC III Acquisition Corp. receives a Avoid rating with a composite score of 33.7/100 (rank #4233 of 7,333). Our quantitative framework assigns a Narrow Moat (40/100, trend: stable), High uncertainty, and Standard capital allocation. The average factor score across quality, value, momentum, stability, and investment is 28/100.
Our analysis does not support a constructive view on ASPAC III Acquisition Corp. at this time. The combination of the current quantitative profile, high uncertainty, and standard capital allocation suggests unfavorable risk-reward at current levels. We recommend investors avoid new positions and existing holders consider reducing exposure.
Analysis derived from Blank Capital Research quantitative terminal. For informational purposes only. No trade solicitation. Past performance not indicative of future results. Consult a qualified advisor.
We assign ASPAC III Acquisition Corp. a Narrow Moat rating with a composite moat score of 40/100. The company possesses identifiable competitive advantages, though they are less entrenched than those of wide-moat peers. Our analysis indicates that ASPAC III Acquisition Corp. can sustain above-average returns on invested capital for at least 10 years, with the strongest contributor being economic value creation at 17.5/20.
The strongest moat sources are economic value creation (17.5/20) and margin superiority (10/20). ROE proxy 126.6% (sector 8.9%). GM N/A vs sector 77%, OM N/A vs sector 17%. These pillars form the core of ASPAC III Acquisition Corp.'s competitive identity and are the primary drivers of excess returns in our framework.
Areas of relative weakness include reinvestment efficiency (0/20) and financial resilience (5.1/20). Capital turnover N/A. Improvement in these areas could meaningfully widen the moat over time, while deterioration would be an early warning of competitive erosion.
Our moat trend assessment is Stable. Multi-year ROIC and operating margin trajectories show neither meaningful improvement nor deterioration, suggesting the competitive position is steady. We expect ASPAC III Acquisition Corp.'s moat profile to remain largely unchanged absent a material shift in return on capital or industry dynamics.
Key profit drivers include returns on equity of 126.6% driving shareholder value creation. Our analysis indicates that profit quality raises some durability concerns, with the quality factor at the 24th percentile.
Return metrics include ROE of 126.6% and ROA of 1.9%. Relative to the Finance, Insurance, And Real Estate sector, sector comparison data is limited, and ROE of 126.6% compares to a sector median of 8.9%.
The balance sheet reflects moderate leverage with D/E of 54%. The sector median D/E is 0%, putting ASPAC III Acquisition Corp. at higher leverage than the typical peer. Overall balance sheet health is adequate for the current business environment.
Above 50MA
37.18%
Net New Highs
+51081
A SPAC III Acquisition Corp. (the "Company"), a blank check company incorporated as a British Virgin Islands exempted company formed for the purpose of effecting a merger, share exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses, today announced the closing of its previously announced initial public offering of 5,500,000 units at an offering price of $10.00 per unit, with each unit consisting of one Class A ordinary share and o
A SPAC III Acquisition Corp. (the "Company"), a blank check company incorporated as a British Virgin Islands exempted company formed for the purpose of effecting a merger, share exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses, today announced the pricing of its initial public offering of 5,500,000 units at an offering price of $10.00 per unit, with each unit consisting of one Class A ordinary share and one right. Each right

Gainers Quoin Pharmaceuticals, Ltd. (NASDAQ: QNRX) shares surged 360.5% to settle at $19.80 on Wednesday on above-average volume. ECMOHO Limited (NASDAQ: MOHO) jumped 146.1% to settle at $0.4085 on above-average volume. Helius Medical Technologies, Inc. (NASDAQ: HSDT) shares climbed 145.3% to close at $1.58 on Wednesday after dropping 13% on Tuesday. Kaspien Holdings Inc. (NASDAQ: KSPN) jumped 140.3% to close at $6.20. Enveric Biosciences, Inc. (NASDAQ: ENVB) gained 106% to settle at $13.10. Enveric Biosciences recently announced an $8 million registered direct offering and private placement. Heart Test Laboratories, Inc. (NASDAQ: HSCS) jumped 89.6% to close at $3.28. Poseida Therapeutics, Inc. (NASDAQ: PSTX) shares surged 85.6% to close at $4.51 as the company entered into a strategic collaboration and license agreement with Roche Holdings AG, focused on developing allogeneic CAR-T therapies directed to hematologic malignancies. Eargo, Inc. (NASDAQ: EAR) shares gained 75.6% to settle at $1.23. The company is scheduled to report Q2 earnings on Monday, August 8. Winc, Inc. (NYSE: WBEV) rose 71.4% to close at $2.16. Cuentas Inc. (NASDAQ: CUEN) gained 70.1% to close at $0.9014. Shares of several companies in the broader communications, entertainment and media industry traded higher amid strength in the overall market and positive overall market sentiment following recent earnings. Ping Identity Holding Corp. (NYSE: PING) shares jumped 60.7% to close at $28.08 after the company announced it will be acquired by Thoma Bravo for $28.50 per share in cash. Ping Identity also posted a Q2 loss of $0.34 per share. American Rebel Holdings, Inc. (NASDAQ: AREB) gained 58.7% to settle at $1.00. Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) surged 49.3% to settle at $212.01 after the company announced the results from its APOLLO-B Phase 3 study of patisiran met the primary endpoint and also met the first secondary endpoint. MediaCo Holding Inc. (NASDAQ: MDIA) jumped 49.1% to settle at $5.65 after climbing around 14% on Tuesday. Standard General recently purchased roughly 12.9 million shares, bringing ownership to 92.4%. Otonomy, Inc. (NASDAQ: OTIC) gained 48.4% to close at $0.37. Otonomy recently announced it will discontinue development of OTO-313 after the Phase 2 trial of OTO-313 in patients with tinnitus demonstrated no clinically meaningful improvement versus placebo for primary and secondary endpoints across all timepoints. Applied DNA Sciences, Inc. (NASDAQ: APDN) jumped 46.4% to close at $4.10 on continued strength after the company initiated analytical validation of a Company-developed, PCR-based monkeypox virus test that is specific for the genetic signature of the monkeypox virus. NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) gained 45.8% to close at $1.75 after the company announced a $3.5 million accelerated milestone payment from Zimmer Biomet. The amendment will also provide Zimmer with 350,000 warrants with an exercise price of $3.00 per share. Chembio Diagnostics, Inc. (NASDAQ: CEMI) shares rose 42.5% to close at $1.04. Chembio Diagnostics is expected to release financial results for the second quarter after the close of trading on Thursday, August 4, 2022. Kintara Therapeutics, Inc. (NASDAQ: KTRA) rose 38.3% to close at $0.2450 after the company entered into an equity purchase agreement with Lincoln Park Capital for up to $20 million. Akso Health Group (NASDAQ: AHG) jumped 37.6% to close at $1.30. Connexa Sports Technologies Inc. (NASDAQ: CNXA) gained 35.2% to settle at $1.46. Shares of several companies in the broader consumer discretionary sector traded higher amid overall market strength. Lottery.com Inc. (NASDAQ: LTRY) jumped 34.3% to settle at $0.4701. Brickell Biotech, Inc. (NASDAQ: BBI) gained 33% to close at $4.19. Tupperware Brands Corporation (NYSE: TUP) surged 32.4% to close at $9.53 after the company reported better-than-expected Q2 results. Senseonics Holdings, Inc. (NYSE: SENS) gained 31.5% to settle at $1.67. Alaunos Therapeutics, Inc. (NASDAQ: TCRT) climbed 31.4% to close at $1.55. Leju Holdings Limited (NYSE: LEJU) gained 28.5% to settle at $2.9931. SoFi Technologies, Inc. (NASDAQ: SOFI) climbed 28.4% to close at $8.23 after the company reported better-than-expected Q2 results and raised FY22 guidance. Endo International plc ...

Gainers Helius Medical Technologies, Inc. (NASDAQ: HSDT) shares jumped 167% to $1.72 after dropping 13% on Tuesday. Kaspien Holdings Inc. (NASDAQ: KSPN) gained 112.4% to $5.48. Eargo, Inc. (NASDAQ: EAR) shares climbed 102.8% to $1.42. The company is scheduled to report Q2 earnings on Monday, August 8. Poseida Therapeutics, Inc. (NASDAQ: PSTX) shares jumped 99.6% to $4.85 as the company entered into a strategic collaboration and license agreement with Roche Holdings AG, focused on developing allogeneic CAR-T therapies directed to hematologic malignancies. Applied DNA Sciences, Inc. (NASDAQ: APDN) climbed 75.7% to $4.92 on continued strength after the company initiated analytical validation of a Company-developed, PCR-based monkeypox virus test that is specific for the genetic signature of the monkeypox virus. Kintara Therapeutics, Inc. (NASDAQ: KTRA) gained 70% to $0.3013 after the company entered into an equity purchase agreement with Lincoln Park Capital for up to $20 million. Ping Identity Holding Corp. (NYSE: PING) shares climbed 59.8% to $27.92 after the company announced it will be acquired by Thoma Bravo for $28.50 per share in cash. Ping Identity also posted a Q2 loss of $0.34 per share. Otonomy, Inc. (NASDAQ: OTIC) jumped 56% to $0.3887. Otonomy recently announced it will discontinue development of OTO-313 after the Phase 2 trial of OTO-313 in patients with tinnitus demonstrated no clinically meaningful improvement versus placebo for primary and secondary endpoints across all timepoints. Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) jumped 48% to $210.17 after the company announced the results from its APOLLO-B Phase 3 study of patisiran met the primary endpoint and also met the first secondary endpoint. Chembio Diagnostics, Inc. (NASDAQ: CEMI) shares gained 48% to $1.08. Chembio Diagnostics is expected to release financial results for the second quarter after the close of trading on Thursday, August 4, 2022. NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) gained 40% to $1.6850 after the company announced a $3.5 million accelerated milestone payment from Zimmer Biomet. The amendment will also provide Zimmer with 350,000 warrants with an exercise price of $3.00 per share. Endo International plc (NASDAQ: ENDP) gained 38% to $0.8099. Tupperware Brands Corporation (NYSE: TUP) jumped 37% to $9.90 after the company reported better-than-expected Q2 results. Tuniu Corporation (NASDAQ: TOUR) shares rose 25.2% to $1.0094 after dropping over 9% on Tuesday. Rubius Therapeutics, Inc. (NASDAQ: RUBY) jumped 24% to $0.85. ECMOHO Limited (NASDAQ: MOHO) gained 23.7% to $0.2054. Clearwater Paper Corporation (NYSE: CLW) rose 22.3% to $42.56 following strong quarterly sales. Donnelley Financial Solutions, Inc. (NASDAQ: DFIN) jumped 22.2% to $41.06 after the company reported better-than-expected Q2 results. SoFi Technologies, Inc. (NASDAQ: SOFI) rose 22.1% to $7.84 after the company reported better-than-expected Q2 results and raised FY22 guidance. Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) jumped 20.2% to $23.43. Arcutis Biotherapeutics priced its ...

U.S. stocks traded higher this morning, with the Dow Jones gaining more than 100 points on Wednesday. Following the market opening Wednesday, the Dow traded up 0.45% to 32,540.68 while the NASDAQ rose 1.43% to 12,525.90. The S&P also rose, gaining, 0.71% to 4,120.15. Also check this: Starbucks, Yum! Brands And 3 Stocks To Watch Heading Into Wednesday Leading and Lagging Sectors Communication services shares climbed 1.7% on Wednesday. Meanwhile, top gainers in the sector included Perion Network Ltd. (NASDAQ: PERI), up 7% and Golden Matrix Group, Inc. (NASDAQ: GMGI) up 8%. In trading on Wednesday, utilities shares fell 1.1%. Top Headline The ISM Services PMI unexpectedly rose to 56.7 in July, recording the highest level in three months, compared to June’s reading of 55.3. However, analysts were expecting a reading of 53.5. Equities Trading UP Poseida Therapeutics, Inc. (NASDAQ: PSTX) shares shot up 108% to $5.05 as the company entered into a strategic collaboration and license agreement with Roche Holdings AG, focused on developing allogeneic CAR-T therapies directed to hematologic malignancies. Shares of Applied DNA Sciences, Inc. (NASDAQ: APDN) got a boost, shooting 76% to $4.9284 on continued strength after the company initiated analytical validation of a Company-developed, PCR-based monkeypox virus test that is specific for the genetic ...